USPTO Patent US12584138B2 for Genetic Modification Immunotherapies

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12584138B2 to ImmunityBio, Inc. for a quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies. The patent covers modified NK-92® cells and methods for treating cancer.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12584138B2 to ImmunityBio, Inc. The patent, titled "Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies," details modified NK-92® cells designed for enhanced cellular immunotherapy. The granted claims cover specific genetic modifications, including the incorporation of homing receptors, chimeric antigen receptors (CARs), Fc Receptors, and cytokines, along with methods for their use in treating cancer.

This patent grant signifies a new intellectual property asset for ImmunityBio, Inc. in the field of cancer immunotherapy. While not a regulatory rule imposing obligations on other entities, it represents a significant development in the biotechnology sector. Companies operating in similar therapeutic areas should be aware of this granted patent as it may impact their freedom to operate or require licensing considerations for related technologies. No immediate compliance actions are required for external entities, but legal and R&D departments should note this patent for strategic planning.

Source document (simplified)

← USPTO Patent Grants

Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies

Grant US12584138B2 Kind: B2 Mar 24, 2026

Assignee

ImmunityBio, Inc.

Inventors

Hans G. Klingemann, Laurent H. Boissel, Nathan T. Schomer

Abstract

Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Recpetor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.

CPC Classifications

C12N 15/625 C12N 5/0646 C12N 15/85 C12N 15/90 C12N 2510/00 C12N 2750/14143 A61K 9/0029 A61K 40/15 A61K 40/31 A61K 40/4211 A61K 40/4219 A61K 2239/31 A61K 2239/38 A61K 2239/48 A61K 48/00 A61K 35/17 A61K 2121/00 A61K 2300/00 A61P 35/02 A61P 35/00 C07K 14/5443 C07K 14/55 C07K 14/7051 C07K 14/70553 C07K 14/70564 C07K 14/70596 C07K 14/82 C07K 14/521 C07K 14/5434 C07K 14/70535 C07K 14/7158 C07K 16/2827 C07K 14/71 C07K 2317/622 C07K 2319/03 C07K 2319/33 C07K 2319/74 A01K 2207/12 A01K 2227/105 A01K 2267/0331 H10D 30/6745 H10D 64/669 H10D 84/038 H10D 89/817